pharmaphorum

APRIL 26, 2022

Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The interest in how the human microbiome influences health has grown substantially in the last decade.

Immunization 115

Immunization FDA 115

Outsourcing Pharma

APRIL 26, 2022

The companyâs Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.

97

97

pharmaphorum

APRIL 26, 2022

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in fundraising in the first quarter. The Boston-based startup – which has a business model straddling digital therapeutics (DTx), artificial intelligence-powered patient management and provision of virtual care – said the Series D will be used to fund clinical trials of its DTx candidates, scale up its v

Hospitals 98

Hospitals FDA 98

Fossil Remedies

APRIL 26, 2022

PCD Pharma Business Plan. In a pharmaceutical business, you need a link between the pharma marketing company and the end-user, i.e., doctors, pharmacists, or others who can prescribe the medicine. This connecting link is the PCD Pharma Business. The full form of PCD is Propaganda Cum Distribution. Are you a person who wants to know about the details of preparing a successful PCD pharma business plan?

Documentation 59

Documentation 59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 26, 2022

Making sure clinical trials are diverse and representative of the populations they’re studying isn’t just the right thing to do to promote inclusivity and equity; it’s also just good science/clinical scientific practice. But despite growing efforts to improve, many organisers still fall short when it comes to reaching, recruiting and retaining diverse patient populations in clinical trials.

FDA 98

FDA 98

Roots Analysis

APRIL 26, 2022

Women’s digital health involves the initiatives taken by industry stakeholders and researchers, which include technological remedies, such as mobile apps, software, wearable devices and diagnostic tools that exclusively aid in improving female health and wellness. Since it is primarily focused on women’s healthcare, it is termed as Female Technology or FemTech.

52

52

Outsourcing Pharma

APRIL 26, 2022

The decentralized clinical trial specialist has acquired CureClick to add to its offerings a platform intended to expand awareness of study participation.

52

52

pharmaphorum

APRIL 26, 2022

There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer’s VLA15 – and it has just moved another step closer to being available. The two partners have reported positive results in a phase 2 trial in paediatric patients aged five to 17, backing up earlier results in adults and setting up the start of a pivotal phase 3 trial in the third quarter of this year.

Vaccines 69

Vaccines 69

Outsourcing Pharma

APRIL 26, 2022

The US agency has expanded its approval of Veklury to include use in pediatric patients 28 days and older who have tested positive for the COVID-19 virus.

FDA 52

FDA 52

pharmaphorum

APRIL 26, 2022

Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in trials of its immuno-oncology candidate bempegaldesleukin, which was discontinued last week. The move affects around 500 employees, and will allow Nektar to extend its cash reserves – which were valued at around $730 million at the end of last year – into the first half of 2025.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

APRIL 26, 2022

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates

42

42

pharmaphorum

APRIL 26, 2022

With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic, navigating the complex landscape and optimizing clinical strategy to rev

52

52

Pharma Times

APRIL 26, 2022

The Foundation also launched a new collaboration with Diabetes UK and the Juvenile Diabetes Research Foundation UK

45

45

pharmaphorum

APRIL 26, 2022

Abbott has revamped the digital health app used alongside its neurostimulation devices for chronic pain, making it easier for doctors to track how well patients are managing the treatment. The Neurosphere myPath app is designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy using Abbott’s Proclaim device range.

Documentation 52

Documentation 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

APRIL 26, 2022

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in the coming months. The two partners say the ReSTORE trial of rezafungin, a drug in the echinocandin class, met its objectives in showing that rezafungin was as effective as daily dosing with the decades-old drug caspofungin for candida infections.

FDA 52

FDA 52

pharmaphorum

APRIL 26, 2022

Join us on Tuesday 26th April for a webinar, bought to you in association with IQVIA, where key industry figures from IQVIA and Boehringer Ingelheim, along with Integrated Care System Strategy experts, will be discussing the future of the Health and Care Bill and the importance of collaborations between ICS leaders to address system readiness to improve population health.

40

40

pharmaphorum

APRIL 26, 2022

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform. The two phase 1 trials of the California biotech’s lead CAR-NK candidates showed that the therapies were able to induce complete responses in two groups of patients with hard-to-treat, heavily pre-treated blood cancers, and appeared easier to tolerate than current CAR-T therapies.

52

52